

The simplified Pentacel® and Quadracel® immunization series incorporates

A VACCINATION SCHEDULE WITH FEWER INJECTIONS¹⁻⁴

CDC SCHEDULE THROUGH 6 YEARS OF AGE³

Incorporation of Pentacel and Quadracel vaccines on the immunization schedule

VACCINE	AGE	BIRTH	1 MONTH	2 MONTHS	4 MONTHS	6 MONTHS	12 MONTHS	15 MONTHS	18 MONTHS	19-23 MONTHS	2-3 YEARS	4-6 YEARS
Hepatitis B		Hep B	Hep B			Hep B						
Diphtheria, tetanus, pertussis				Pentacel®				Pentacel®				Quadracel®
Inactivated poliovirus				Pentacel®				Pentacel®				
<i>Haemophilus influenzae</i> type b												Hib
Rotavirus				RV	RV	RV†						
Pneumococcal conjugate				PCV	PCV	PCV	PCV					PCV
Influenza (2 doses for some)							Influenza (yearly)					
Measles, mumps, rubella						MMR†	MMR					MMR
Varicella							Varicella					Varicella
Hepatitis A							Hep A (2-dose series)				Hep A (2-dose series)	
Meningococcal				MenACWY								
Pneumococcal polysaccharide											PPSV	

RV = Respiratory syncytial virus; PCV = Pneumococcal conjugate vaccine; MMR = Measles, mumps, and rubella.

● Range of recommended ages for all children

● Range of recommended ages for certain high-risk groups

Adapted from: Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2022.

Vaccination schedules may vary based on patients' overall health status.³

*Depending on the type of vaccine used, a 3rd dose may be required.³

†For certain high-risk groups, a dose at 6-11 months of age is recommended.

INDICATION FOR PENTACEL AND QUADRACEL


Pentacel is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to *H influenzae* type b. Pentacel is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).


Quadracel is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel is approved as a fifth dose in the diphtheria, tetanus, pertussis (DTaP) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (IPV) vaccination series, in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Pentacel and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), and/or VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).

IMPORTANT SAFETY INFORMATION FOR PENTACEL AND QUADRACEL

Contraindications to vaccination with Pentacel or Quadracel include: a severe allergic reaction (e.g., anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or *Haemophilus influenzae* type b vaccine (Pentacel only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Please see Important Safety Information continued on the following page. Prescribing Information for Pentacel or Quadracel (49281-564-10/15 and 49281-562-10).

 **Pentacel®**
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine

 **Quadracel®**
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine

IMPORTANT SAFETY INFORMATION FOR PENTACEL AND QUADRACEL (continued)

Carefully consider benefits and risks before administering Pentacel or Quadracel to persons with a history of: fever $\geq 105^{\circ}\text{F}$, hypotonic-hyposensitive episode, or persistent, inconsolable crying lasting ≥ 3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Pentacel or Quadracel or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel and for the next 24 hours.

Apnea following intramuscular vaccination has been observed in some infants born prematurely.

Syncope (fainting) may occur in association with administration of injectable vaccines including Pentacel and Quadracel. Procedures should be in place to avoid injury from fainting.

The most common local and systemic adverse reactions to Pentacel include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Pentacel or Quadracel may not protect all individuals.

Prescribing Information for Pentacel or Quadracel (49281-564-10/15 and 49281-562-10).

References: 1. Pentacel. Prescribing Information. NDC No. 49281-0511-05. Sanofi Pasteur Limited. 2. Quadracel. Prescribing Information. NDC No. 49281-564-10/15. Sanofi Pasteur Limited; Quadracel. Prescribing Information. NDC No. 49281-562-10. Sanofi Pasteur Limited. 3. Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2022. <https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>. Accessed October 17, 2022. 4. Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, 2022

CPT Code for Pentacel vaccine: 90698**

CPT Code for Quadracel vaccine: 90696

*CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

Pentacel is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.

Quadracel is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

